WO2024176199 - PRODUCTION OF NOVEL ANTI-RTL1 ANTIBODY WITH SPECIFIC IDENTIFICATION CAPABILITY FOR HUMAN TISSUE GRANULOCYTES AND MACROPHAGES
National phase entry is expected:
Publication Number
WO/2024/176199
Publication Date
29.08.2024
International Application No.
PCT/IB2024/052083
International Filing Date
04.03.2024
Title **
[English]
PRODUCTION OF NOVEL ANTI-RTL1 ANTIBODY WITH SPECIFIC IDENTIFICATION CAPABILITY FOR HUMAN TISSUE GRANULOCYTES AND MACROPHAGES
[French]
PRODUCTION D'UN NOUVEL ANTICORPS ANTI-RTL1 AVEC UNE CAPACITÉ D'IDENTIFICATION SPÉCIFIQUE POUR DES GRANULOCYTES ET DES MACROPHAGES TISSULAIRES HUMAINS
Applicants **
EMTIAZI, Nikoo
Inventors
EMTIAZI, Nikoo
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1882 | |
| EPO | Filing, Examination, Granting | 8732 | |
| Japan | Filing, Examination, Granting | 1983 | |
| South Korea | Filing, Examination, Granting | 1632 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
22,569
Contact Us
Abstract[English]
This invention is related to research antibodies with practical applications. there have been various markers for identifying granulocytes, macrophages, and also macrophages, and neutrophils associated with tumors. This invention introduces the protein RTL1, using a specific antibody against it, as a completely specific and new marker in peripheral blood granulocytes, tissue macrophages, and macrophages and neutrophils in human cancerous tissue. After selecting the peptide and conjugating it with the KLH protein, injections were made into rabbits to produce polyclonal antibodies. the antibodies, immunized from rabbit serum, were sorted using chromatography columns with the peptide ligand. Finally, the specificity of the antibodies to granulocytes, macrophages, and also macrophages and neutrophils associated with tumors was evaluated through flow cytometry techniques and immunohistochemistry on tissues. one of the potential applications of these antibodies is the purification and isolation of these cells, as well as the targeting of macrophages, tumor-associated granulocytes in cancer immunotherap[French]
Cette invention concerne la recherche d'anticorps ayant des applications pratiques. Divers marqueurs permettent d'identifier des granulocytes, des macrophages, ainsi que des macrophages, et des neutrophiles associés à des tumeurs. Cette invention introduit la protéine RTL1, à l'aide d'un anticorps spécifique contre celui-ci, en tant que nouveau marqueur complètement spécifique dans des granulocytes sanguins périphériques, des macrophages tissulaires, et des macrophages et des neutrophiles dans un tissu cancéreux humain. Après la sélection du peptide et sa conjugaison avec la protéine KLH, des injections ont été effectuées dans des lapins pour produire des anticorps polyclonaux. Les anticorps, immunisés à partir de sérum de lapin, ont été triés à l'aide de colonnes de chromatographie avec le ligand peptidique. Enfin, la spécificité des anticorps vis-à-vis des granulocytes, des macrophages, ainsi que des macrophages et des neutrophiles associés à des tumeurs a été évaluée par des techniques de cytométrie en flux et une immunohistochimie sur des tissus. L'une des applications potentielles de ces anticorps est la purification et l'isolement de ces cellules, ainsi que le ciblage de macrophages, de granulocytes associés à une tumeur dans un immunothérapie contre le cancer.